Foghorn Therapeutics Unveils Strong Preclinical Oncology Data at AACR for Multiple Programs
FHTX sits 61% above its 52-week low of $3.27.
Summary
Foghorn Therapeutics presented robust preclinical data at the AACR Annual Meeting, demonstrating complete tumor regression for its lead candidate FHD-909 and strong results for multiple degrader programs, significantly bolstering its oncology pipeline.
Key Events · Product Development and Regulatory · FHTX
-
Compelling Preclinical Data for FHD-909
The SMARCA2 selective inhibitor FHD-909 demonstrated complete and durable tumor regression, along with anti-tumor immune memory, when combined with an anti-PD-1 antibody in preclinical syngeneic mouse models. This is a strong positive signal for the lead candidate currently in Phase 1.
-
Positive Results for Selective CBP Degrader
The selective CBP degrader FHT-171 showed strong anti-tumor activity as a monotherapy and a favorable tolerability profile in preclinical models of heavily pretreated ER+ breast cancer, indicating potential for a new therapeutic option.
-
Superior Efficacy for Selective EP300 Degrader
Foghorn's selective EP300 degrader outperformed a clinical benchmark (inobrodib) in preclinical multiple myeloma models, demonstrating enhanced safety and efficacy, including tumor regression in pomalidomide-resistant models.
-
Progress with Selective ARID1B Degrader
The company reported robust degradation with its cereblon-based selective ARID1B degraders, designed for potential oral bioavailability, marking progress on this previously intractable target for ARID1A-mutant cancers.
Analysis · FHTX · Life Sciences
Foghorn Therapeutics announced compelling preclinical data for its lead SMARCA2 inhibitor, FHD-909, showing complete and durable tumor regression with immune memory in combination with an anti-PD-1 antibody. This is a significant positive development for their oncology pipeline, especially as FHD-909 is already in Phase 1. Additionally, the company reported favorable efficacy and tolerability for its selective CBP degrader in ER+ breast cancer models and superior efficacy for its selective EP300 degrader in multiple myeloma compared to a clinical benchmark. Progress with the selective ARID1B degrader program further strengthens the pipeline. These results, presented at AACR, provide strong validation for Foghorn's chromatin regulatory system platform and could de-risk future clinical development, potentially attracting further investment or partnerships. The company also noted a cash runway into H1 2028, providing financial stability for these advancements.
At the time of this filing, FHTX was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $309.4M. The 52-week trading range was $3.27 to $6.95. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.